Vir Biotechnology (VIR) director Coughlin reports zero share ownership
Rhea-AI Filing Summary
Vir Biotechnology, Inc. director Timothy Coughlin filed an initial Form 3 reporting his beneficial ownership of the company’s common stock. The filing shows he directly owns 0 shares of common stock following the reported position as of June 9, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Coughlin Timothy
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 0 shares (Direct)
Key Figures
Common shares owned: 0 shares
1 metrics
Common shares owned
0 shares
Total shares following reported position as of June 9, 2026
Key Terms
Form 3, beneficial ownership, Common Stock
3 terms
Form 3 regulatory
"director Timothy Coughlin filed an initial Form 3 reporting his beneficial ownership"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"filed an initial Form 3 reporting his beneficial ownership of the company’s common stock"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Common Stock financial
"The filing shows he directly owns 0 shares of common stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Timothy Coughlin’s Form 3 for Vir Biotechnology (VIR) show?
The Form 3 shows that director Timothy Coughlin reported beneficial ownership of 0 shares of Vir Biotechnology common stock as of June 9, 2026, indicating no directly owned position at that time.
Is Timothy Coughlin a director of Vir Biotechnology (VIR)?
Yes. The filing identifies Timothy Coughlin as a director of Vir Biotechnology, Inc. Directors are required to report their beneficial ownership of the company’s securities using SEC Form 3 when they become insiders.
Does Timothy Coughlin report any derivative securities in Vir Biotechnology (VIR)?
No derivative securities are listed. The derivativeSummary section is empty, and there are no option, warrant, or other derivative positions reported for Timothy Coughlin in this Form 3 filing.
Are there any buy or sell transactions in this Vir Biotechnology (VIR) Form 3?
No. The filing is categorized as a holding entry with an unknown transaction code and shows 0 shares owned. It does not report any purchases, sales, or exercises of Vir Biotechnology securities.